mCig, Inc. (MCIG) Applauds the FDAs Decision to Delay Enforcement of E-Cig Rules

“mCig Inc. applauds this sensible and responsible decision by the FDA, as the scientific data continues to demonstrate that vaping is shown to be a less-harmful alternative to traditional, combustible cigarettes. mCig agrees with the American Vaping Association, that the near term e-cig enforcement would ban 99 percent of vaping products on the market and cause many to return to harmful and often fatal use of traditional cigarettes. As science and the will of the people confirm the wisdom of our business model concerning smoke alternative products and the vaping industry, I am confident the same will ring true with our core business model surrounding the cannabis and CBD industries. This means long term growth, viability, and value for our shareholders,” said Paul Rosenberg, CEO of mCig.

Following the details of the deeming regulations released last year, and the uncertainty it created for the U.S. market, mCig had shifted its business strategy and energy to international markets. This strategy proved widely effective with mCig now serving 4 continents and over 20 countries with its VitaCig brand, representing over $5M in projected revenue over the course of the next two years.

mCig also reclaimed non-performing international franchises to enhance shareholder value. As a result, the sole corporation now operates under the VitaCig name with full control and ownership of all its European distribution channels, previous branding for VitaStik, an EU Trademark (which includes all member states of the EU), 14 domain names (including vitastik.de, vitastikofficial.com), and all other European trade secrets of the Vitastik brand in all member states of the European Union; with additional trademark protection in Australia, Mexico, and Turkey.

Following Friday’s landmark decision by the FDA, mCig and its E-Cig Division will now refocus its efforts on the U.S., utilizing best practices which have driven international growth. As successful and popular as our original VitaCig vitamin and essential oil e-cig product line has become, the non-nicotine market only accounts for approximately 20% of the $4 billion dollar vape industry, while nicotine based vape products make up the other 80%. With Friday’s update from the FDA allowing us to market our nicotine products for an additional five years, mCig will once again expand its arsenal of vape and e-cig products by relaunching its widely popular VitaCig18 and VitaJuice nicotine product lines. This will allow us to tap into that larger piece of the vape/e-cig market, and scale our revenues greater than before. mCig will also re-engage several lucrative distribution deals and investment opportunities that were on hold while awaiting more feedback and clarity from the FDA.

As part of our aggressive national U.S. strategy, mCig Inc., along with Goodtrade Corp, will launch vitaciglatino.com, a Spanish only VitaCig online e-commerce website later this week. The Joint Venture initiative will focus on direct marketing, advertising, and investment geared toward the 55 million Spanish speaking Americans in the U.S., and the approximately 450 million native Spanish speakers around the world. mCig is confident this unique strategic initiative will generate significant additional revenue for the company, and will help to further expand brand awareness worldwide.

About MCIG Group ( OTCQB : MCIG )
Headquartered in Henderson, Nevada, with offices in Temecula, California, mCig, Inc. (OTCQB : MCIG ) is a diversified company servicing the legal Cannabis, Hemp, and CBD markets. mCig, Inc. is committed to being the leading distributor of technology, products, and services to fit the needs of a rapidly expanding industry. mCig, Inc. has transitioned from a vaporizer manufacturer to industry leading large scale, full service cannabis cultivation construction company with its Grow Contractors division currently operating in the rapidly expanding the Nevada market.